The Westin Philadelphia
Philadelphia, PA

March 15 - 16, 2019

CME/CE Credit

 Upon completion of this activity, participants should be better able to:

  • Identify benefits and disadvantages of the various colon cleansing strategies.
  • Outline the recommended screening tests for colorectal cancer.
  • Identify and address barriers to colorectal cancer screening.
  • Integrate current SCENIC international consensus recommendations for CRC screening in patients with IBD.
  • Integrate evidence-based approach to the diagnosis of esophageal motility disorders.
  • Discuss treatment strategies for patients with esophageal motility disorders.
  • Delineate a noninvasive diagnostic approach for GERD.
  • Differentiate between common gastrointestinal disorders: IBS, IBD, peptic ulcer disease.
  • Describe new and emerging management strategies for IBS.
  • Delineate the role of biosimilar therapies in the management of IBD.
  • Review the most current perspectives and clinical guidelines for the management of inflammatory bowel disease (IBD).
  • Integrate routine testing for H. pylori prior to and after treatment for peptic ulcer.
  • Identify patients with peptic ulcer disease for whom PPIs are indicated.
  • Describe expanded donor organ criteria and novel technologies for improved organ preservation.
  • Discuss the emerging paradigm for diagnosis and management of acute pancreatitis.
  • Identify appropriate candidates with acute pancreatitis for minimally invasive approaches to treatment.
  • Integrate current approaches to the diagnosis and management of cirrhotic cardiomyopathy.
  • Develop evidence-based prevention and management strategy for gut dysbiosis in liver disease
  • Identify factors that may be used to predict which patients with compensated cirrhosis may transition to decompensated cirrhosis.
  • Assess optimal management strategies for patients with decompensated cirrhosis and its consequences, including hepatic encephalopathy and hepatorenal syndrome.
  • Outline the screening recommendations for hepatitis B.
  • Discuss diagnostic and monitoring recommendations for HBV.
  • Outline the treatment recommendations for HCV.
  • Delineate factors that increase risk for HCC in order to optimize early recognition and diagnosis.
  • Describe challenges in the management of hepatocellular carcinoma.
  • Discuss populations at risk for NASH.
  • Delineate treatment strategies for NASH.
  • Develop a diagnostic evaluation strategy for patients suspected of having alcoholic hepatitis/advanced liver disease.
  • Discuss medical treatments and lifestyle modifications to manage AH.
  • Discuss pruritis as a potential symptom of primary biliary cholangitis (PBC).
  • Identify first- and second-line treatments for PBC.

In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and Global Academy for Medical Education. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This knowledge-based activity qualifies for 13.25 contact hours of continuing pharmacy education credit. Pharmacists should claim only those contact hours actually spent participating in the activity.

This activity is awarded 13.25 contact hours. (60 minute CH) Nurses should only claim those contact hours actually spent participating in the activity.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 13.25 Category 1 credits for completing this activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAFP Credit
This Live activity, 6th Annual Digestive Diseases: New Advances , with a beginning date of 03/15/2019, has been reviewed and is acceptable for up to 13.25 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Follow Us

Jointly Provided By